CSL
CSL Ltd (CSL.AX) surged 24.15% in a week to A$169.41 after reporting FY2026 results with a A$2.6B statutory loss but better-than-expected underlying profit and FY27 guidance. Analysts raised targets to A$160–193, citing a valuation reset and buyback. The stock is overbought (RSI 82.3) but analysts see further upside.
CSL stock rose 3.3% to A$171.91 on Thursday, extending a rally after reporting FY26 results. Revenue was US$15.8B, net profit US$3.1B, both above expectations. The company guided for 5% profit growth in FY27 and announced a A$1.1B share buyback. Analysts upgraded price targets, citing improved plasma business trends and cost savings.
CSL (ASX: CSL) shares surged 5.49% to an overbought RSI of 83.66, the highest on the ASX 200. The stock is up 85% in 7 weeks after a May low, driven by a guidance reset and pipeline updates. Revenue and profit guidance for FY26 were cut, but markets saw it as a reset. Recent regulatory and clinical updates have mixed implications. The company expects growth in FY27.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CSL.AX (CSL). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent CSL.AX coverage spans earnings and financial news.
Earnings beat and upgraded guidance plus a A$1.1B buyback support a near‑term rally with upside to A$180‑193.
Earnings beat and buyback support near‑term upside.
Technical momentum shift may attract short‑term traders but no new fundamental catalyst is disclosed.
alphai scores every news story that mentions CSL.AX with an AI model for sentiment and relevance, and aggregates insider trades from CSL's SEC EDGAR Form 4 filings. Figures refresh continuously.
CSL Ltd (CSL.AX) surged 24.15% in a week to A$169.41 after reporting FY2026 results with a A$2.6B statutory loss but better-than-expected underlying profit and FY27 guidance. Analysts raised targets to A$160–193, citing a valuation reset and buyback. The stock is overbought (RSI 82.3) but analysts see further upside.
3 min readCSL stock rose 3.3% to A$171.91 on Thursday, extending a rally after reporting FY26 results. Revenue was US$15.8B, net profit US$3.1B, both above expectations. The company guided for 5% profit growth in FY27 and announced a A$1.1B share buyback. Analysts upgraded price targets, citing improved plasma business trends and cost savings.
2 min readCSL (ASX: CSL) shares surged 5.49% to an overbought RSI of 83.66, the highest on the ASX 200. The stock is up 85% in 7 weeks after a May low, driven by a guidance reset and pipeline updates. Revenue and profit guidance for FY26 were cut, but markets saw it as a reset. Recent regulatory and clinical updates have mixed implications. The company expects growth in FY27.
2 min read
